Zacks Investment Research
03 Jul 2026, 18:40 UTC · 1h ago
Is it Apt to Retain Haemonetics Stock in Your Portfolio for Now?
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Zacks Investment Research
03 Jul 2026, 18:40 UTC · 1h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
4 claims · each scored for market impact
Haemonetics' Plasma franchise returned to growth in Q4 fiscal 2026 with organic revenue growth of 13%. — Positive organic growth in a core business unit suggests improving fundamental momentum.
+0.40Haemonetics signed new long-term agreements with BioLife and Grifols in fiscal 2025. — Secured long-term contracts with major partners provide revenue visibility and stability.
+0.30Haemonetics faces challenges from a debt-burdened balance sheet and fierce competitive pressure. — High debt and competition act as headwinds to valuation and operational margins.
-0.30The company's shares have lost 2.4% over the past year, underperforming the S&P 500's 22.8% growth. — Significant underperformance relative to the broader market indicates weak investor sentiment.
Continue reading
6 related stories
Top 1 mover · tap to explore
Which stocks this story touches
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
GlobeNewsWire
1h ago
